智通财经APP讯,迈博药业-B(02181)发布2024年度业绩,营业收入 2.58亿元(人民币,下同),同比增长196.3%;净亏损1.28亿元,同比收窄38.9%;每股基本亏损0.03元。
期内集团的营业收入由同比增加,主要是因为报告期内集团CMAB009药品新上市和CMAB007、CMAB008药品销售稳固增长以及独家推广许可权收入及CMAB806的合同研发生产协议收入增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.